

## **Cynata Receives Notice of Decision to Grant a Patent from Chinese Patent Office**

**Melbourne, Australia; 28 February 2022:** Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that a notice of a decision to grant a patent has been received from the State Intellectual Property Office of the People’s Republic of China (SIPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell (MSC) technology. The patent application, entitled “Colony Forming Medium and Use Thereof”, is wholly owned by Cynata.

The decision to grant a patent is sent to the applicant (Cynata) when the SIPO intends to issue a patent. The patent will build further on an extensive patent estate surrounding the Cymerus manufacturing platform and its unique ability to yield highly consistent MSCs at scale, from a single donation, to create therapeutic stem cell products. Cynata’s extensive IP portfolio already includes issued patents in a wide range of commercially important markets, including Japan, Europe and the USA.

### **Dr Ross Macdonald, Cynata’s Chief Executive Officer, said:**

*“This wholly Cynata-owned patent encompasses novel aspects of the manufacturing process of Cynata’s Cymerus MSC products and joins an extensive list of issued patents protecting our unique and proprietary IP. China is an enormously important market as its economy continues to grow and the central government accelerates the pace of adoption of sophisticated, cutting-edge medicines. This achievement will be of significant assistance in our ongoing engagement with potential partners in China. The Cymerus platform enables manufacture of consistent, high-quality MSCs at scale. This unique and valuable characteristic of Cynata’s technology is key to the development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide”.*

Cynata anticipates that the patent will be granted in May 2022, with an expiration date of 14 March 2037.

The inventors named on the patent are Professor Igor Slukvin, founder, advisor and shareholder of Cynata, Dr Gene Uenishi, Ms Diana Drier and Dr Derek Hei.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

**CONTACTS:** Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Lauren Nowak, Media Contact, +61 (0)400 434 299, [laurenmaree@live.com.au](mailto:laurenmaree@live.com.au)

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.



Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Planning for a Phase 2 clinical trial in GvHD is presently underway. Clinical trials of Cymerus products in osteoarthritis (Phase 3), respiratory failure and diabetic foot ulcers (DFU) are currently ongoing. In addition, Cynata has demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

**Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.**